Ventyx Biosciences, Inc. Financials
This page shows Ventyx Biosciences, Inc. (VTYX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Ventyx Biosciences, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Ventyx Biosciences, Inc. generates $0.97 in operating cash flow (-$130.9M OCF vs -$135.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Ventyx Biosciences, Inc.'s EBITDA was -$148.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 28.7% from the prior year.
Ventyx Biosciences, Inc. reported -$135.1M in net income in fiscal year 2024. This represents an increase of 30.0% from the prior year.
Ventyx Biosciences, Inc. earned $-1.97 per diluted share (EPS) in fiscal year 2024. This represents an increase of 40.3% from the prior year.
Cash & Balance Sheet
Ventyx Biosciences, Inc. generated -$131.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 21.5% from the prior year.
Ventyx Biosciences, Inc. held $27.3M in cash against $0 in long-term debt as of fiscal year 2024.
Ventyx Biosciences, Inc. had 71M shares outstanding in fiscal year 2024. This represents an increase of 20.1% from the prior year.
Margins & Returns
Ventyx Biosciences, Inc.'s ROE was -53.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 25.9 percentage points from the prior year.
Capital Allocation
Ventyx Biosciences, Inc. invested $117.0M in research and development in fiscal year 2024. This represents a decrease of 33.4% from the prior year.
Ventyx Biosciences, Inc. invested $241K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 53.1% from the prior year.
VTYX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $17.7M-20.5% | $22.3M-2.8% | $22.9M | N/A | $30.6M+10.2% | $27.8M-17.6% | $33.7M | N/A |
| SG&A Expenses | $7.2M+1.4% | $7.1M-1.8% | $7.2M | N/A | $7.9M+0.2% | $7.9M-1.4% | $8.0M | N/A |
| Operating Income | -$24.9M+15.2% | -$29.3M+2.5% | -$30.1M | N/A | -$38.6M-8.0% | -$35.7M+14.5% | -$41.8M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$22.8M+15.4% | -$27.0M+1.7% | -$27.4M | N/A | -$35.2M-10.3% | -$31.9M+17.2% | -$38.6M | N/A |
| EPS (Diluted) | $-0.32+15.8% | $-0.38+2.6% | $-0.39 | N/A | $-0.500.0% | $-0.50+19.4% | $-0.62 | N/A |
VTYX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $211.5M-8.1% | $230.0M-9.3% | $253.5M-8.3% | $276.6M-8.1% | $301.1M-2.6% | $309.2M-6.9% | $332.1M+19.6% | $277.7M |
| Current Assets | $201.1M-8.3% | $219.3M-9.6% | $242.6M+5.6% | $229.6M-20.7% | $289.4M+12.6% | $256.9M-19.6% | $319.8M+21.0% | $264.3M |
| Cash & Equivalents | $32.0M-1.0% | $32.3M+15.0% | $28.1M+3.0% | $27.3M-55.9% | $61.8M+50.9% | $40.9M-71.2% | $141.9M+175.1% | $51.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $20.1M-2.5% | $20.6M-5.6% | $21.8M-3.0% | $22.5M+0.9% | $22.3M-21.4% | $28.4M+13.2% | $25.1M-25.7% | $33.8M |
| Current Liabilities | $11.3M-1.8% | $11.5M-7.5% | $12.4M-3.0% | $12.8M+3.8% | $12.3M-32.0% | $18.1M+24.6% | $14.5M-34.7% | $22.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $191.4M-8.6% | $209.4M-9.6% | $231.6M-8.8% | $254.0M-8.9% | $278.8M-0.7% | $280.8M-8.5% | $307.0M+25.9% | $243.9M |
| Retained Earnings | -$631.6M-3.8% | -$608.7M-4.6% | -$581.7M-5.0% | -$554.3M-5.6% | -$525.0M-7.2% | -$489.7M-7.0% | -$457.8M-9.2% | -$419.2M |
VTYX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.5M+17.7% | -$21.3M+17.3% | -$25.7M-10.6% | -$23.2M+34.4% | -$35.5M-44.5% | -$24.5M+48.5% | -$47.6M+7.8% | -$51.7M |
| Capital Expenditures | $50K+19.0% | $42K+162.5% | $16K+166.7% | $6K | $0-100.0% | $60K-65.7% | $175K-17.1% | $211K |
| Free Cash Flow | -$17.6M+17.6% | -$21.3M+17.2% | -$25.7M-10.7% | -$23.3M+34.4% | -$35.5M-44.2% | -$24.6M+48.5% | -$47.8M+7.8% | -$51.9M |
| Investing Cash Flow | $17.1M-32.3% | $25.2M-4.6% | $26.4M+340.2% | -$11.0M-137.6% | $29.2M+138.7% | -$75.5M-280.8% | $41.8M-9.5% | $46.1M |
| Financing Cash Flow | $203K | N/A | N/A | -$25K-100.1% | $26.9M+3064.9% | -$906K-100.9% | $96.2M+16341.7% | $585K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VTYX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -11.9%+1.0pp | -12.9%-1.0pp | -11.8% | N/A | -12.6%-1.3pp | -11.4%+1.2pp | -12.6% | N/A |
| Return on Assets | -10.8%+0.9pp | -11.7%-0.9pp | -10.8% | N/A | -11.7%-1.4pp | -10.3%+1.3pp | -11.6% | N/A |
| Current Ratio | 17.86-1.3 | 19.12-0.4 | 19.57+1.6 | 17.97-5.6 | 23.52+9.3 | 14.19-7.8 | 22.00+10.1 | 11.87 |
| Debt-to-Equity | 0.100.0 | 0.100.0 | 0.090.0 | 0.090.0 | 0.08-0.0 | 0.10+0.0 | 0.08-0.1 | 0.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Ventyx Biosciences, Inc. profitable?
No, Ventyx Biosciences, Inc. (VTYX) reported a net income of -$135.1M in fiscal year 2024.
What is Ventyx Biosciences, Inc.'s EBITDA?
Ventyx Biosciences, Inc. (VTYX) had EBITDA of -$148.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ventyx Biosciences, Inc.'s return on equity (ROE)?
Ventyx Biosciences, Inc. (VTYX) has a return on equity of -53.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Ventyx Biosciences, Inc.'s free cash flow?
Ventyx Biosciences, Inc. (VTYX) generated -$131.1M in free cash flow during fiscal year 2024. This represents a 21.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ventyx Biosciences, Inc.'s operating cash flow?
Ventyx Biosciences, Inc. (VTYX) generated -$130.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Ventyx Biosciences, Inc.'s total assets?
Ventyx Biosciences, Inc. (VTYX) had $276.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Ventyx Biosciences, Inc.'s capital expenditures?
Ventyx Biosciences, Inc. (VTYX) invested $241K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Ventyx Biosciences, Inc. spend on research and development?
Ventyx Biosciences, Inc. (VTYX) invested $117.0M in research and development during fiscal year 2024.
What is Ventyx Biosciences, Inc.'s current ratio?
Ventyx Biosciences, Inc. (VTYX) had a current ratio of 17.97 as of fiscal year 2024, which is generally considered healthy.
What is Ventyx Biosciences, Inc.'s debt-to-equity ratio?
Ventyx Biosciences, Inc. (VTYX) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ventyx Biosciences, Inc.'s return on assets (ROA)?
Ventyx Biosciences, Inc. (VTYX) had a return on assets of -48.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Ventyx Biosciences, Inc.'s cash runway?
Based on fiscal year 2024 data, Ventyx Biosciences, Inc. (VTYX) had $27.3M in cash against an annual operating cash burn of $130.9M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Ventyx Biosciences, Inc.'s Piotroski F-Score?
Ventyx Biosciences, Inc. (VTYX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ventyx Biosciences, Inc.'s earnings high quality?
Ventyx Biosciences, Inc. (VTYX) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.